All In Biotech

Drug Trial Radar · NCT01882803

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Sep 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

129

Actual

Start

Jun 17, 2013

Primary completion

Nov 18, 2020

Study completion Nov 18, 2020

Sponsor

Lead sponsor
SecuraBioIndustry
Sponsor type
Industry
First posted
Jun 20, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in participants with indolent non-Hodgkin lymphoma (iNHL) (follicular lymphoma \[FL\], marginal zone lymphoma, or small lymphocytic lymphoma) that was refractory to rituximab and to either chemotherapy or radioimmunotherapy (RIT).

Conditions

  • Indolent Non-Hodgkin Lymphoma

Interventions

  • DuvelisibDrug

    Phosphoinositide-3-kinase (PI3K) inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Every 8-16 weeks while on treatment with duvelisib for up to 72 months

Locations

69 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Whittier, California

  • Site not named

    Denver, Colorado

  • Site not named

    Fort Myers, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tallahassee, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    St Louis, Missouri

  • Site not named

    Howell Township, New Jersey

  • Site not named

    Morristown, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Rockville Centre, New York

  • Site not named

    Canton, Ohio

  • Site not named

    Lawton, Oklahoma

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Nashville, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Lynchburg, Virginia

  • Site not named

    Brest, Belarus

  • Site not named

    Minsk, Belarus

  • Site not named

    Vitebsk, Belarus

  • Site not named

    Lyasny, Minsk Oblast, Belarus

  • Site not named

    Ghent, Belgium

  • Site not named

    Kortrijk, Belgium

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Gatineau, Quebec, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Brno, Czechia

  • Site not named

    Ostrava-Poruba, Czechia

  • Site not named

    Angers, France

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.